Smith+Nephew Appoints Thérèse Esperdy as Senior Independent Director Designate

Smith & Nephew Snats ( (SNN) ) just unveiled an update.

Smith+Nephew has announced the appointment of Thérèse Esperdy as an independent Non-Executive Director and Senior Independent Director designate, effective December 1, 2025. Esperdy, who brings extensive experience from her roles in financial services and as a board member of international businesses, will succeed Angie Risley following the company’s AGM in May 2026. This strategic appointment is expected to enhance the company’s governance and strengthen its board with Esperdy’s expertise, particularly in highly regulated industries.

The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats’ strong financial performance and positive earnings call outlook are the primary drivers of its stock score. While technical indicators show mixed momentum, and valuation suggests the stock may be expensive, the company’s robust cash flow and strategic initiatives support a positive outlook. Challenges in emerging markets and potential tariff impacts are notable risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith+Nephew is a global medical technology company specializing in the repair, regeneration, and replacement of soft and hard tissue. The company operates through three main business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in 1856 in Hull, UK, Smith+Nephew now operates in over 100 countries and reported annual sales of $5.8 billion in 2024. It is a constituent of the FTSE100.

Average Trading Volume: 664,265

Technical Sentiment Signal: Buy

Current Market Cap: $15.7B

For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.